FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Emmanuel Favaloro

Research Profile

Disorders

Chemicals & Drugs

Procedures

Physiology

Anatomy

Concepts & Ideas

Activities & Behaviors

Quality Control

Co-author Network

Publications

TOP 3
Emmanuel Favaloro
Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants.
Ashraf Mina; Emmanuel Favaloro; Jerry Koutts
A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding.
Emmanuel Favaloro; Roslyn Bonar; Katherine Marsden
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Emmanuel Favaloro (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emmanuel Favaloro
Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants.
International journal of laboratory hematology 2013;35(3):269-74.
2012: Ashraf Mina; Emmanuel Favaloro; Jerry Koutts
A novel flow cytometry single tube bead assay for quantitation of von Willebrand factor antigen and collagen-binding.
Thrombosis and haemostasis 2012;108(5):999-1005.
2012: Emmanuel Favaloro; Roslyn Bonar; Katherine Marsden
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal.
Journal of thrombosis and haemostasis : JTH 2012;10(7):1455-8; author reply 1458-60.
2012: Emmanuel Favaloro; Richard C W Wong
The antiphospholipid syndrome: diagnosis, pathogenesis, laboratory testing, and management.
Seminars in thrombosis and hemostasis 2012;38(4):299-304.
2012: Emmanuel Favaloro; Susan Jovanovich; Peter J Roberts-Thomson; Loretta Wheatland; Richard C W Wong
Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I--Anticardiolipin and anti-β2-glycoprotein I antibodies.
Seminars in thrombosis and hemostasis 2012;38(4):390-403.
2012: Emmanuel Favaloro; Roslyn Bonar; Katherine Marsden
Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II--Lupus anticoagulant.
Seminars in thrombosis and hemostasis 2012;38(4):404-11.
2012: Geoff Kershaw; Emmanuel Favaloro
Laboratory identification of factor inhibitors: an update.
Pathology 2012;44(4):293-302.
2012: Emmanuel Favaloro; Roslyn Bonar; K Chapman; M Meiring; D Funk Adcock
Differential sensitivity of von Willebrand factor (VWF) 'activity' assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays.
Journal of thrombosis and haemostasis : JTH 2012;10(6):1043-54.
2012: Roslyn Bonar; Emmanuel Favaloro; Geoff Kershaw; Katherine Marsden; Soma Mohammed; David Rosenfeld; Diane Zebeljan; Mark Hertzberg
Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP.
Pathology 2012;44(3):240-7.
2012: Emmanuel Favaloro; S Mohammed; R Reben; J Koutts
Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations.
Internal medicine journal 2012;42(4):427-34.
2012: Emmanuel Favaloro; J Koutts
2B or not 2B? Masquerading as von Willebrand disease?
Journal of thrombosis and haemostasis : JTH 2012;10(2):317-9.
2011: Emmanuel Favaloro
Assessment for antithrombin deficiency in the real world.
International journal of laboratory hematology 2011;33(6):656-8; author reply 659-60.
2011: Emmanuel Favaloro
Thrombocytopenic platelet disorders.
Seminars in thrombosis and hemostasis 2011;37(6):615-6.
2011: Giuseppe Lippi; Emmanuel Favaloro
Laboratory diagnostics and appropriate care of people with haemophilia.
Haemophilia : the official journal of the World Federation of Hemophilia 2011;17(5):824-5.
2011: Emmanuel Favaloro; James Favaloro; Roslyn Bonar; Jerry Koutts
Diagnosis and management of von Willebrand disease in Australia.
Seminars in thrombosis and hemostasis 2011;37(5):542-54.
2011: Emmanuel Favaloro
Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder.
Seminars in thrombosis and hemostasis 2011;37(5):440-55.
2011: Emmanuel Favaloro; R Bonar
External quality assurance for the PFA-100®.
Journal of thrombosis and haemostasis : JTH 2011;9(4):878-80.
2010: Emmanuel Favaloro; R Bonar; D Zebeljan; Geoff Kershaw; K Marsden
Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required.
Journal of thrombosis and haemostasis : JTH 2010;8(12):2828-31.
2010: Emmanuel Favaloro; S Mohammed; J McDonald
Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay.
Journal of thrombosis and haemostasis : JTH 2010;8(12):2842-4.
2010: Giuseppe Lippi; Emmanuel Favaloro; Martina Montagnana; Massimo Franchini
C-reactive protein and venous thromboembolism: causal or casual association?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2010;48(12):1693-701.
2010: Emmanuel Favaloro
Seminars in Thrombosis and Hemostasis. Foreword.
Seminars in thrombosis and hemostasis 2010;36(8):803-4.
2010: Emmanuel Favaloro; Giuseppe Lippi; Maarten T M Raijmakers; Huib L Vader; Fedde van der Graaf
Discard tubes are sometimes necessary when drawing samples for hemostasis.
American journal of clinical pathology 2010;134(5):851.
2010: Emmanuel Favaloro
Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
Thrombosis and haemostasis 2010;104(5):1009-21.
2010: Giuseppe Lippi; Gianfranco Cervellin; Massimo Franchini; Emmanuel Favaloro
Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.
Journal of thrombosis and thrombolysis 2010;30(4):459-71.
2010: Emmanuel Favaloro
Global hemostasis: new approaches to patient diagnosis and treatment monitoring. Foreword.
Seminars in thrombosis and hemostasis 2010;36(7):693-4.
2010: Emmanuel Favaloro
Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008-2009.
Seminars in thrombosis and hemostasis 2010;36(7):685-92.
2010: Emmanuel Favaloro
Hemolytic uremic syndrome. Preface.
Seminars in thrombosis and hemostasis 2010;36(6):573-4.
2010: Emmanuel Favaloro; Wendy McVicker; Sayed Hamdam; Naomi Hocker
Improving the harmonisation of the International Normalized Ratio (INR): time to think outside the box?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2010;48(8):1079-90.
2010: Giuseppe Lippi; Emmanuel Favaloro
Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?
Seminars in thrombosis and hemostasis 2010;36(5):558-69.
2010: Giuseppe Lippi; Massimo Franchini; Emmanuel Favaloro
Thrombotic complications of erythropoiesis-stimulating agents.
Seminars in thrombosis and hemostasis 2010;36(5):537-49.
2010: Giuseppe Lippi; Emmanuel Favaloro
Recombinants in thrombosis and hemostasis: from basic research to clinical therapy.
Seminars in thrombosis and hemostasis 2010;36(5):471-6.
2010: Emmanuel Favaloro; Roslyn Bonar; Geoff Kershaw; S Mohammed; Elizabeth Duncan; Katherine Marsden
Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia.
Haemophilia : the official journal of the World Federation of Hemophilia 2010;16(4):662-70.
2010: Emmanuel Favaloro; G Lippi
Problems in laboratory testing: hemophilia and beyond.
Journal of thrombosis and haemostasis : JTH 2010;8(5):1119-20.
2010: G Lippi; Emmanuel Favaloro; M Montagnana; G C Guidi
Prevalence of hypokalaemia: the experience of a large academic hospital.
Internal medicine journal 2010;40(4):315-6.
2010: Ashraf Mina; Emmanuel Favaloro; Soma Mohammed; Jerry Koutts
A laboratory evaluation into the short activated partial thromboplastin time.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2010;21(2):152-7.
2010: Giuseppe Lippi; Gian Luca Salvagno; D M Adcock; Matteo Gelati; Gian Cesare Guidi; Emmanuel Favaloro
Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample.
International journal of laboratory hematology 2010;32(1 Pt 2):132-8.
2010: Emmanuel Favaloro
Genetic testing for von Willebrand disease: the case against.
Journal of thrombosis and haemostasis : JTH 2010;8(1):6-12.
2009: Emmanuel Favaloro; David McDonald; Giuseppe Lippi
Laboratory investigation of thrombophilia: the good, the bad, and the ugly.
Seminars in thrombosis and hemostasis 2009;35(7):695-710.
2009: Giuseppe Lippi; Mario Plebani; Massimo Franchini; Gian Cesare Guidi; Emmanuel Favaloro
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Seminars in thrombosis and hemostasis 2009;35(7):654-64.
2009: Massimo Franchini; Martina Montagnana; Emmanuel Favaloro; Giuseppe Lippi
The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread.
Seminars in thrombosis and hemostasis 2009;35(7):644-53.
2009: Giuseppe Lippi; Massimo Franchini; Emmanuel Favaloro
Unsuspected triggers of venous thromboembolism--trivial or not so trivial?
Seminars in thrombosis and hemostasis 2009;35(7):597-604.
2009: Giuseppe Lippi; Massimo Franchini; Emmanuel Favaloro
Coagulopathies and thrombosis: usual and unusual causes and associations, Part II.
Seminars in thrombosis and hemostasis 2009;35(7):591-5.
2009: Emmanuel Favaloro; Jim Thom; David Patterson; Sarah Just; Maria Baccala; Tracy Dixon; Muriel Meiring; Jerry Koutts; John Rowell; Ross Baker
Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2009;20(6):475-83.
2009: Elizabeth M Duncan; R Bonar; Susan E Rodgers; Emmanuel Favaloro; K Marsden
Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program.
International journal of laboratory hematology 2009;31(4):398-406.
2009: Giuseppe Lippi; Emmanuel Favaloro; Gian Luca Salvagno; Massimo Franchini
Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside.
Clinica chimica acta; international journal of clinical chemistry 2009;405(1-2):8-16.
2009: Giuseppe Lippi; Martina Montagnana; Emmanuel Favaloro; Massimo Franchini
Mental depression and cardiovascular disease: a multifaceted, bidirectional association.
Seminars in thrombosis and hemostasis 2009;35(3):325-36.
2009: Massimo Franchini; Giuseppe Lippi; Emmanuel Favaloro
Coagulopathies and thrombosis: usual and unusual causes and associations, part I.
Seminars in thrombosis and hemostasis 2009;35(3):257-9.
2009: Emmanuel Favaloro; Jim Thom; David Patterson; Sarah Just; Tracy Dixon; Jerry Koutts; Maria Baccala; John Rowell; Ross Baker
Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Thrombosis research 2009;123(6):862-8.
2009: Emmanuel Favaloro
Internal quality control and external quality assurance of platelet function tests.
Seminars in thrombosis and hemostasis 2009;35(2):139-49.
2009: Catherine P M Hayward; Emmanuel Favaloro
Diagnostic evaluation of platelet disorders: the past, the present, and the future.
Seminars in thrombosis and hemostasis 2009;35(2):127-30.
2009: Emmanuel Favaloro
Toward a new paradigm for the identification and functional characterization of von Willebrand disease.
Seminars in thrombosis and hemostasis 2009;35(1):60-75.
2009: Giuseppe Lippi; Emmanuel Favaloro; Massimo Franchini; Gian Cesare Guidi
Milestones and perspectives in coagulation and hemostasis.
Seminars in thrombosis and hemostasis 2009;35(1):9-22.
2009: Giuseppe Lippi; Emmanuel Favaloro; Massimo Franchini
Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside.
Seminars in thrombosis and hemostasis 2009;35(1):3-8.
2009: Beryl Dawson; Emmanuel Favaloro
High rate of deficiency in the amino acids tryptophan and histidine in people with wounds: implication for nutrient targeting in wound management--a pilot study.
Advances in skin & wound care 2009;22(2):79-82.
2009: Giuseppe Lippi; Gian Cesare Guidi; Massimo Franchini; Emmanuel Favaloro
Relationship between activated partial thromboplastin time, heparin and potassium levels.
Diabetes research and clinical practice 2009;83(2):e33-4.
2009: Emmanuel Favaloro; Richard C W Wong
Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey.
Pathology 2009;41(7):666-75.
2009: Emmanuel Favaloro
The Journal Impact Factor: don't expect its demise any time soon.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1319-24.
2009: Giuseppe Lippi; Massimo Franchini; Emmanuel Favaloro
Pharmacogenetics of vitamin K antagonists: useful or hype?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(5):503-15.
2009: Giuseppe Lippi; Emmanuel Favaloro; Gian Cesare Guidi
The impact factor and journals in laboratory medicine.
Clinical laboratory 2009;55(1-2):49-52.
2009: Giuseppe Lippi; Gian Luca Salvagno; Emmanuel Favaloro; Gian Cesare Guidi
Survey on the prevalence of hemolytic specimens in an academic hospital according to collection facility: opportunities for quality improvement.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(5):616-8.
2009: Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Gian Luca Salvagno; Gian Cesare Guidi; Emmanuel Favaloro
Epidemiological association between fasting plasma glucose and shortened APTT.
Clinical biochemistry 2009;42(1-2):118-20.
2008: Jolanta Kilanowska; Emmanuel Favaloro; Giuseppe Lippi
Aspirin 'responsiveness', 'nonresponsiveness' or 'resistance': a putative role for von Willebrand factor?
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2008;19(8):823-4.
2008: Emmanuel Favaloro
Clinical utility of the PFA-100.
Seminars in thrombosis and hemostasis 2008;34(8):709-33.
2008: Emmanuel Favaloro
A tribute to Eberhard F. Mammen, M.D. (1930-2008).
Seminars in thrombosis and hemostasis 2008;34(8):703-7.
2008: Emmanuel Favaloro
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal.
Journal of thrombosis and haemostasis : JTH 2008;6(11):1999-2001; author reply 2002-3.
2008: Emmanuel Favaloro; Giuseppe Lippi; Dorothy M Adcock
Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?
Seminars in thrombosis and hemostasis 2008;34(7):612-34.
2008: Giuseppe Lippi; Emmanuel Favaloro
Activated partial thromboplastin time: new tricks for an old dogma.
Seminars in thrombosis and hemostasis 2008;34(7):604-11.
2008: Emmanuel Favaloro; Dorothy M Adcock
Standardization of the INR: how good is your laboratory's INR and can it be improved?
Seminars in thrombosis and hemostasis 2008;34(7):593-603.
2008: Emmanuel Favaloro; Giuseppe Lippi; Massimo Franchini
Laboratory diagnostics in thrombosis and hemostasis: the past, the present, and the future.
Seminars in thrombosis and hemostasis 2008;34(7):579-83.
2008: Maha Othman; Emmanuel Favaloro
Genetics of type 2B von Willebrand disease: "true 2B," "tricky 2B," or "not 2B." What are the modifiers of the phenotype?
Seminars in thrombosis and hemostasis 2008;34(6):520-31.
2008: Giuseppe Lippi; Massimo Franchini; Emmanuel Favaloro; Gian Cesare Guidi
Salbutamol in athletes.
Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 2008;18(5):469; author reply 469-70.
2008: Emmanuel Favaloro
A better approach to monitoring of therapy in von Willebrand disease?
Thrombosis and haemostasis 2008;100(3):371-3.
2008: Giuseppe Lippi; Emmanuel Favaloro; Gian Cesare Guidi
The genetic basis of human athletic performance. Why are psychological components so often overlooked?
The Journal of physiology 2008;586(Pt 12):3017; author reply 3019-20.
2008: Emmanuel Favaloro; Richard C W Wong
Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.
Seminars in thrombosis and hemostasis 2008;34(4):389-410.
2008: Richard C W Wong; Emmanuel Favaloro
A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays.
Seminars in thrombosis and hemostasis 2008;34(4):361-72.
2008: Emmanuel Favaloro; Richard C W Wong
Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing.
Seminars in thrombosis and hemostasis 2008;34(4):309-12.
2008: Giuseppe Lippi; Emmanuel Favaloro
Cardiac biomarkers in pulmonary embolism.
Thrombosis and haemostasis 2008;99(6):1134-6.
2008: Emmanuel Favaloro
Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature: only a part of the story.
Thrombosis and haemostasis 2008;99(6):1122-3; author reply 1123.
2008: Giuseppe Lippi; Martina Montagnana; Massimo Franchini; Emmanuel Favaloro; Giovanni Targher
The paradoxical relationship between serum uric acid and cardiovascular disease.
Clinica chimica acta; international journal of clinical chemistry 2008;392(1-2):1-7.
2008: Richard C W Wong; Emmanuel Favaloro
Clinical features, diagnosis, and management of the antiphospholipid syndrome.
Seminars in thrombosis and hemostasis 2008;34(3):295-304.
2008: Richard C W Wong; Emmanuel Favaloro
Antiphospholipid antibodies and the antiphospholipid syndrome. I: pathogenesis, clinical features, diagnosis, and management. Preface.
Seminars in thrombosis and hemostasis 2008;34(3):213-8.
2008: Emmanuel Favaloro; Richard C W Wong
Dedication: Professor Ronald A. Asherson, M.D. (Hon), F.R.C.P., M.D., F.A.C.P., F.C.P., F.A.C.R., Dip. O&G (Hon) [1934-2008].
Seminars in thrombosis and hemostasis 2008;34(3):211.
2008: Emmanuel Favaloro; Sayed Hamdam; Jane McDonald; Wendy McVicker; Violeta Ule
Time to think outside the box? Prothrombin time, international normalised ratio, international sensitivity index, mean normal prothrombin time and measurement of uncertainty: a novel approach to standardisation.
Pathology 2008;40(3):277-87.
2008: Jie Jin Wang; Robert J Ross; Jingsheng Tuo; George Burlutsky; Ava G Tan; Chi-Chao Chan; Emmanuel Favaloro; Andrew Williams; Paul Mitchell
The LOC387715 polymorphism, inflammatory markers, smoking, and age-related macular degeneration. A population-based case-control study.
Ophthalmology 2008;115(4):693-9.
2008: Emmanuel Favaloro
von Willebrand disease, type 2B: A diagnosis more elusive than previously thought.
Thrombosis and haemostasis 2008;99(3):630-1; author reply 632-3.
2008: Emmanuel Favaloro
Can blood flow assays help to identify clinically relevant differences in von Willebrand factor functionality in von Willebrand disease types 1-3?
Journal of thrombosis and haemostasis : JTH 2008;6(3):545-6.
2008: Emmanuel Favaloro
Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
Seminars in thrombosis and hemostasis 2008;34(1):113-27.
2008: Emmanuel Favaloro
Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story.
Seminars in thrombosis and hemostasis 2008;34(1):7-25.
2008: Emmanuel Favaloro
Hot topics II: an editorial collection of current issues and controversies in thrombosis and hemostasis.
Seminars in thrombosis and hemostasis 2008;34(1):3-6.
2008: Giuseppe Lippi; Emmanuel Favaloro
Detection of duplicates and redundancies. A major responsibility of peer-reviewers?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(12):1796-7.
2008: Giuseppe Lippi; Giuseppe Banfi; Emmanuel Favaloro; Joern Rittweger; Nicola Maffulli
Updates on improvement of human athletic performance: focus on world records in athletics.
British medical bulletin 2008;87():7-15.
2008: Emmanuel Favaloro; Roslyn Bonar; Katherine Marsden
Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
Clinical laboratory science : journal of the American Society for Medical Technology 2008;21(3):178-83.
2008: Ashraf Mina; Emmanuel Favaloro; Jerry Koutts
A practical approach to instrument selection, evaluation, basic financial management and implementation in pathology and research.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(9):1223-9.
2008: Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Emmanuel Favaloro
Help me, Doctor! My D-dimer is raised.
Annals of medicine 2008;40(8):594-605.
2008: Giuseppe Lippi; Emmanuel Favaloro; Massimo Franchini; Gian Cesare Guidi
Air pollution and coagulation testing: a new source of biological variability?
Thrombosis research 2008;123(1):50-4.
2008: Emily Blyth; Emmanuel Favaloro; David Harris; Lukas Kairaitis
Protein Z is reduced in chronic kidney disease and not elevated in patients on haemodialysis.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2008;19(1):23-5.
2008: Richard C W Wong; Emmanuel Favaloro; Stephen Adelstein; Karl Baumgart; R Bird; T A Brighton; MArianne Empson; David Gillis; Michelle J Hendle; R Laurent; D Mallon; Wendy Pollock; S Smith; Richard H Steele; Robert J Wilson
Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting.
Pathology 2008;40(1):58-63.
2008: Alfonso Iorio; Chris Barnes; Maria Cristina Vedovati; Emmanuel Favaloro
Thrombophilia and cerebral vein thrombosis.
Frontiers of neurology and neuroscience 2008;23():55-76.
2007: Ashraf Mina; Emmanuel Favaloro; Jerry Koutts
Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.
Seminars in thrombosis and hemostasis 2007;33(8):798-809.
2007: Emmanuel Favaloro; Geoff Kershaw; Andrew J McLachlan; John Lloyd
Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease.
Seminars in thrombosis and hemostasis 2007;33(8):745-58.
2007: Emmanuel Favaloro
An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult.
Seminars in thrombosis and hemostasis 2007;33(8):727-44.
2007: Emmanuel Favaloro; David Patterson; Anna Denholm; Scott Mead; Ann Gilbert; Anne Collins; Jane Estell; Peter M George; Mark P Smith
Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis.
British journal of haematology 2007;139(4):623-6.
2007: Emmanuel Favaloro; Roslyn Bonar; Elizabeth Duncan; Gail Earl; Joyce Low; Margaret Aboud; Sarah Just; John Sioufi; Alison Street; Katherine Marsden
Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation.
Pathology 2007;39(5):504-11.
2007: Emmanuel Favaloro
More on the Impact Factor and thrombosis and haemostasis journals: benefits and limitations.
Thrombosis and haemostasis 2007;98(2):475-6.
2007: Emmanuel Favaloro; Roslyn Bonar; Muriel Meiring; Alison Street; Katherine Marsden
2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
Thrombosis and haemostasis 2007;98(2):346-58.
2007: Emmanuel Favaloro; Roslyn Bonar; Elizabeth Duncan; Susan Rodgers; Katherine Marsden
Utility of the PFA-100 as a screening test of platelet function: an audit of haemostasis laboratories in Australia and New Zealand.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(5):441-8.
2007: Emmanuel Favaloro; John Lloyd; John Rowell; Ross Baker; Kevin Rickard; Geoff Kershaw; Alison Street; Kate Scarff; Giulio Barrese; Darryl Maher; Andrew J McLachlan
Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Thrombosis and haemostasis 2007;97(6):922-30.
2007: Kathy H C Wu; Ava G Tan; Elena Rochtchina; Emmanuel Favaloro; Andrew Williams; Paul Mitchell; Jie Jin Wang
Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case-control study.
Investigative ophthalmology & visual science 2007;48(5):1983-8.
2007: Emmanuel Favaloro
Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations.
Seminars in thrombosis and hemostasis 2007;33(3):290-7.
2007: Emmanuel Favaloro; Roslyn Bonar
Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.
Seminars in thrombosis and hemostasis 2007;33(3):235-42.
2007: Emmanuel Favaloro
Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?
Haematologica 2007;92(3):292-6.
2007: Emmanuel Favaloro; Richard C W Wong; Susan Jovanovich; Peter J Roberts-Thomson
A Review of beta2 -glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program.
American journal of clinical pathology 2007;127(3):441-8.
2007: Emmanuel Favaloro; Roslyn Bonar; Lesley Survela; David McDonald; Jerry Koutts; John Sioufi; Katherine Marsden
The diagnostic dilemma: dual presentations of clinical mucosal bleeding and venous thrombosis associated with the presence of thrombophilia markers and mild reduction in von Willebrand factor.
Laboratory hematology : official publication of the International Society for Laboratory Hematology 2007;13(4):128-34.
2007: Emmanuel Favaloro
Preanalytical variables in coagulation testing.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2007;18(1):86-9.
2006: Emmanuel Favaloro
Increased propensity to bruising in red-haired females: a possible role for von Willebrand factor?
Anesthesia and analgesia 2006;103(6):1622-3.
2006: Emmanuel Favaloro
2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease.
British journal of haematology 2006;135(1):141-2; author reply 143.
2006: J Evan Sadler; Ulrich Budde; J C J Eikenboom; Emmanuel Favaloro; Frank G H Hill; Lars Holmberg; Jørgen Ingerslev; C A Lee; D Lillicrap; P M Mannucci; Claudine Mazurier; Dominique Meyer; W L Nichols; M Nishino; Ian R Peake; Francesco Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; Augusto B Federici
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
Journal of thrombosis and haemostasis : JTH 2006;4(10):2103-14.
2006: Emmanuel Favaloro
Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
Seminars in thrombosis and hemostasis 2006;32(6):566-76.
2006: Emmanuel Favaloro
More on: platelet function analyser (PFA)-100 closure time in the evaluation of platelet disorders and platelet function.
Journal of thrombosis and haemostasis : JTH 2006;4(9):2099-100.
2006: R Coleman; Emmanuel Favaloro; Soma Soltani; T B Keng
Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor.
Journal of thrombosis and haemostasis : JTH 2006;4(9):2085-8.
2006: Emmanuel Favaloro
The utility of the PFA-100 in the identification of von Willebrand disease: a concise review.
Seminars in thrombosis and hemostasis 2006;32(5):537-45.
2006: Emmanuel Favaloro; Roslyn Bonar; Geoff Kershaw; John Sioufi; Ross Baker; Mark Hertzberg; Alison Street; Katherine Marsden
Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program.
Seminars in thrombosis and hemostasis 2006;32(5):505-13.
2006: Emmanuel Favaloro
Laboratory identification of von Willebrand disease: technical and scientific perspectives.
Seminars in thrombosis and hemostasis 2006;32(5):456-71.
2006: Emmanuel Favaloro
More on 'universal'versus'selected' screening for thrombophilia: the hidden costs of false-positive diagnosis.
British journal of haematology 2006;134(2):239-40; author reply 241.
2006: Emmanuel Favaloro; Roslyn Bonar; Elizabeth Duncan; Gail Earl; Joyce Low; Margaret Aboud; Sarah Just; John Sioufi; Alison Street; Katherine Marsden
Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation.
Thrombosis and haemostasis 2006;96(1):73-8.
2006: B Dawson; Emmanuel Favaloro; J Taylor; A Aggarwal
Unrecognized pellagra masquerading as odynophagia.
Internal medicine journal 2006;36(7):472-4.
2006: Emmanuel Favaloro
Effect of overnight 4 degrees C storage of whole blood on von Willebrand factor.
Transfusion 2006;46(6):1057-9; author reply 1059-60.
2006: R C W Wong; Emmanuel Favaloro
The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-beta2-glycoprotein-1 ELISAs: a rebuttal.
Journal of thrombosis and haemostasis : JTH 2006;4(6):1434-5; author reply 1435-7.
2006: Emmanuel Favaloro
2B or not 2B? What is the role of VWF in platelet-matrix interactions? And what is the role of the VWF:CB in VWD diagnostics? These are the questions.
Journal of thrombosis and haemostasis : JTH 2006;4(4):892-4.
2006: Martina Böhm; Susanne Täschner; Evelyne Kretzschmar; Rüdiger Gerlach; Emmanuel Favaloro; Inge Scharrer
Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2006;17(1):39-45.
2006: Emmanuel Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton
Activated protein C resistance: the influence of ABO-blood group, gender and age.
Thrombosis research 2006;117(6):665-70.
2005: Emmanuel Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton; James W C Favaloro
Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
American journal of clinical pathology 2005;124(6):910-7.
2005: Emmanuel Favaloro
Is elevated factor VIII a risk factor for venous thromboembolism in Canada?
Thrombosis and haemostasis 2005;94(5):1112-3.
2005: Emmanuel Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton
Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2005;16(8):597-605.
2005: Margaret A Allman-Farinelli; Kerry Gomes; Emmanuel Favaloro; Peter Petocz
A diet rich in high-oleic-acid sunflower oil favorably alters low-density lipoprotein cholesterol, triglycerides, and factor VII coagulant activity.
Journal of the American Dietetic Association 2005;105(7):1071-9.
2005: Emmanuel Favaloro; Roslyn Bonar; John Sioufi; Michael Wheeler; Joyce Low; Margaret Aboud; John Lloyd; Alison Street; Katherine Marsden
An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin.
Pathology 2005;37(3):234-8.
2005: Mark Hertzberg; Sue Neville; Emmanuel Favaloro; David McDonald
External quality assurance of DNA testing for thrombophilia mutations.
American journal of clinical pathology 2005;123(2):189-93.
2005: Emmanuel Favaloro
Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.
Seminars in thrombosis and hemostasis 2005;31(1):85-9.
2005: Emmanuel Favaloro; Richard C W Wong; Roger Silvestrini; Robert McEvoy; Susan Jovanovich; Peter J Roberts-Thomson
A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing.
Seminars in thrombosis and hemostasis 2005;31(1):73-84.
2005: Emmanuel Favaloro; Roslyn Bonar; John Sioufi; Michael Wheeler; Joyce Low; Margaret Aboud; Elizabeth Duncan; Julian Smith; Thomas Exner; John Lloyd; Katherine Marsden
Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Seminars in thrombosis and hemostasis 2005;31(1):49-58.
2005: Richard C W Wong; Stephen Adelstein; David Gillis; Emmanuel Favaloro
Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.
Seminars in thrombosis and hemostasis 2005;31(1):39-48.
2005: Emmanuel Favaloro
Diagnostic issues in thrombophilia: a laboratory scientist's view.
Seminars in thrombosis and hemostasis 2005;31(1):11-6.
2005: Emmanuel Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton
Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis.
Laboratory hematology : official publication of the International Society for Laboratory Hematology 2005;11(3):174-84.
2005: Emmanuel Favaloro; Roslyn Bonar; Margaret Aboud; Joyce Low; John Sioufi; Michael Wheeler; John Lloyd; Alison Street; Katherine Marsden
How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
Laboratory hematology : official publication of the International Society for Laboratory Hematology 2005;11(3):157-62.
2005: Emmanuel Favaloro; Roslyn Bonar; Geoff Kershaw; John Sioufi; Jim Thom; Ross Baker; Mark Hertzberg; Alison Street; John Lloyd; Katherine Marsden
Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates.
Laboratory hematology : official publication of the International Society for Laboratory Hematology 2005;11(2):91-7.
2004: Emmanuel Favaloro
Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study of 148 patients--a rebuttal.
Journal of thrombosis and haemostasis : JTH 2004;2(12):2280-2; author reply 2283-5.
2004: Emmanuel Favaloro; Soma Soltani; Jane McDonald
Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing.
American journal of clinical pathology 2004;122(5):686-92.
2004: Emmanuel Favaloro; Jennifer Posen; Raj Ramakrishna; Soma Soltani; Simon McRae; Sarah Just; Margaret Aboud; Joyce Low; Rosalie Gemmell; Geoff Kershaw; Robyn Coleman; Mark Dean
Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2004;15(8):637-47.
2004: Emmanuel Favaloro; M Zafer; S C Nair; Mark Hertzberg; K North
Evaluation of primary haemostasis in people with neurofibromatosis type 1.
Clinical and laboratory haematology 2004;26(5):341-5.
2004: Emmanuel Favaloro; D Lillicrap; María A Lazzari; M Cattaneo; C Mazurier; A Woods; Susana S Meschengieser; A Blanco; Ana C Kempfer; A Hubbard; A Chang
von Willebrand disease: laboratory aspects of diagnosis and treatment.
Haemophilia : the official journal of the World Federation of Hemophilia 2004;10 Suppl 4():164-8.
2004: Emmanuel Favaloro; Roslyn Bonar; Geoff Kershaw; John Sioufi; Mark Hertzberg; Alison Street; John Lloyd; Katherine Marsden
Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process.
Haemophilia : the official journal of the World Federation of Hemophilia 2004;10(3):232-42.
2004: Richard Wong; Emmanuel Favaloro; Wendy Pollock; Robert Wilson; Michelle J Hendle; Stephen Adelstein; Karl Baumgart; Paul Homes; Stuart Smith; Richard Steele; Allan Sturgess; David Gillis
A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays.
Pathology 2004;36(2):182-92.
2004: Richard C W Wong; David Gillis; Stephen Adelstein; Karl Baumgart; Emmanuel Favaloro; Michelle J Hendle; Paul Homes; Wendy Pollock; Stewart Smith; Richard H Steele; Allan Sturgess; Robert J Wilson
Consensus guidelines on anti-cardiolipin antibody testing and reporting.
Pathology 2004;36(1):63-8.
2003: Emmanuel Favaloro; Roslyn Bonar; John Sioufi; Mark Hertzberg; Alison Street; John Lloyd; Katherine Marsden
Laboratory diagnosis of von Willebrand disorder. Current practice in the southern hemisphere.
American journal of clinical pathology 2003;119(6):882-93.
2002: Wei Xu; Emmanuel Favaloro; Hans Zoellner
Nitric oxide and prostacyclin are released by cultured apoptotic human umbilical vein endothelial cells consistent with an anti-micro-thrombotic potential.
Thrombosis and haemostasis 2002;88(5):883-4.
2002: Emmanuel Favaloro
A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays.
Haemophilia : the official journal of the World Federation of Hemophilia 2002;8(6):828-31.
2002: Emmanuel Favaloro; Roger Silvestrini
Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing.
American journal of clinical pathology 2002;118(4):548-57.
2002: Emmanuel Favaloro
Clinical application of the PFA-100.
Current opinion in hematology 2002;9(5):407-15.
2002: Mark Hertzberg; Emmanuel Favaloro; Jerry Koutts
Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone.
American journal of hematology 2002;70(4):330-1.
2002: Emmanuel Favaloro; Ina Orsag; Melinda Bukuya; David McDonald
A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Pathology 2002;34(4):348-55.
2002: Susan E Rodgers; Nancy V Lerda; Emmanuel Favaloro; Elizabeth M Duncan; Graeme J Casey; Diana M Quinn; Mark Hertzberg; John V Lloyd
Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods.
American journal of clinical pathology 2002;118(2):269-76.
2002: Emmanuel Favaloro
Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
Seminars in thrombosis and hemostasis 2002;28(2):191-202.
2002: Emmanuel Favaloro; Melinda Bukuya; Teresa Martinelli; Joanne Tzouroutis; Elizabeth Duncan; Katie Welldon; Margaret Collecutt; Heather Aumann; Jim Thom; Grace Gilmore
A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
Thrombosis and haemostasis 2002;87(3):466-76.
2001: Emmanuel Favaloro; S C Nair; C J Forsyth
Collection and transport of samples for laboratory testing in von Willebrand's disease (VWD): time for a reappraisal?
Thrombosis and haemostasis 2001;86(6):1589-90.
2001: Emmanuel Favaloro
Appropriate laboratory assessment as a critical facet in the proper diagnosis and classification of von Willebrand disorder.
Best practice & research. Clinical haematology 2001;14(2):299-319.
2001: W Xu; Emmanuel Favaloro; Heather Medbury; Hans Zoellner
Human endothelial cells maintain anti-aggregatory activity for platelets during apoptosis.
Thrombosis and haemostasis 2001;85(5):915-23.
2001: Emmanuel Favaloro; Geoff Kershaw; Melinda Bukuya; Mark Hertzberg; Jerry Koutts
Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100 and vWF:CBA as combined diagnostic strategies.
Haemophilia : the official journal of the World Federation of Hemophilia 2001;7(2):180-9.
2001: Emmanuel Favaloro
Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.
Haemophilia : the official journal of the World Federation of Hemophilia 2001;7(2):170-9.
2001: Emmanuel Favaloro; M Aboud; C Arthur
Possibility of potential VWD misdiagnosis or misclassification using LIA technology and due to presence of rheumatoid factor.
American journal of hematology 2001;66(1):53-6.
2000: Emmanuel Favaloro; Jim Thom; Ross Baker
Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2000;11(8):729-37.
2000: Emmanuel Favaloro; AJ Henniker; DA Facey; Mark Hertzberg
Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems.
Thrombosis and haemostasis 2000;84(4):541-7.
2000: Emmanuel Favaloro
Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.
American journal of clinical pathology 2000;114(4):608-18.
2000: Emmanuel Favaloro
Sulfatide-binding assay for von Willebrand factor. Detection of von Willebrand's disease without discrimination of vWD subtypes.
Thrombosis research 2000;98(2):213-9.
2000: DA Facey; Emmanuel Favaloro; E Maxwell; Ross Baker; Mark Hertzberg
Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations.
American journal of hematology 2000;63(4):197-9.
2000: Emmanuel Favaloro
Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source.
Thrombosis and haemostasis 2000;83(1):127-35.
2000: M De Luca; DA Facey; Emmanuel Favaloro; Mark Hertzberg; J C Whisstock; T McNally; Robert K Andrews; Michael C Berndt
Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
Blood 2000;95(1):164-72.
1999: Emmanuel Favaloro
Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
Blood reviews 1999;13(4):185-204.
1999: Mark Hertzberg; DA Facey; Emmanuel Favaloro; Jerry Koutts
Type 2B von Willebrand's disease and angiodysplasia.
Thrombosis and haemostasis 1999;82(5):1557-8.
1999: Emmanuel Favaloro; J Smith; P Petinos; M Collecutt; Alison Street; Mark Hertzberg
Laboratory testing, diagnosis, and management of von Willebrand disease. Current practice in Australasia. RCPA Quality Assurance Program in Haematology Scientific Haemostasis Advisory Panel.
American journal of clinical pathology 1999;112(5):712-9.
1999: Mark Hertzberg; T Underwood; Emmanuel Favaloro
Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A.
American journal of hematology 1999;62(3):199-200.
1999: Emmanuel Favaloro; DA Facey; AJ Henniker
Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders.
American journal of hematology 1999;62(3):165-74.
1999: Emmanuel Favaloro; J Smith; P Petinos; Mark Hertzberg; Jerry Koutts
Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel.
Thrombosis and haemostasis 1999;82(4):1276-82.
1999: O Mirochnik; N Halim-Kertanegara; AJ Henniker; Emmanuel Favaloro; C R Tiley; M S Hertzberg; D A McDonald
A novel factor V null mutation at Arg 506 causes a false positive Factor V Leiden result.
Thrombosis and haemostasis 1999;82(3):1198-9.
1999: Emmanuel Favaloro; R Silvestrini; A Mohammed
Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach.
Pathology 1999;31(2):142-7.
1999: DA Facey; Emmanuel Favaloro; Jerry Koutts; M C Berndt; Mark Hertzberg
Identification and characterization of a novel mutation in von Willebrand factor causing type 2B von Willebrand's disease.
British journal of haematology 1999;105(2):538-41.
1999: Emmanuel Favaloro; O Mirochnik; D McDonald
Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
British journal of biomedical science 1999;56(1):23-33.
1999: Margaret A Allman-Farinelli; D Hall; K Kingham; D Pang; Peter Petocz; Emmanuel Favaloro
Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis.
Atherosclerosis 1999;142(1):159-68.
1998: Emmanuel Favaloro
Medical research in New South Wales 1993-1996 assessed by Medline publication capture.
The Medical journal of Australia 1998;169(11-12):617-22.
1998: Margaret A Allman-Farinelli; Linda Bendall; J Troy; C Versluis; D Hall; Emmanuel Favaloro; M C Berndt
A simple, whole blood method for assessment of platelet function: application to dietary intervention.
Thrombosis research 1998;90(4):163-9.
1997: Emmanuel Favaloro; Jerry Koutts
Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease.
Pathology 1997;29(4):385-91.
1997: A Mohammed; P A Mehrabani; R Coombs; L Molesworth; Emmanuel Favaloro
The MDA-180 coagulation analyser: a laboratory evaluation.
Pathology 1997;29(2):176-83.
1996: N Mackinlay; Emmanuel Favaloro; C Arthur; J Smith; M Aboud
A survey of heparin monitoring in Australasia.
Pathology 1996;28(4):343-7.
1996: Zbigniew Rudzki; Elizabeth M Duncan; G J Casey; M Neumann; Emmanuel Favaloro; John V Lloyd
Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods.
British journal of haematology 1996;94(2):400-6.
1995: Emmanuel Favaloro; A Mohammed; R Coombs; P A Mehrabani
Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory.
British journal of biomedical science 1995;52(4):243-8.
1995: V Makrynikola; Emmanuel Favaloro; T Browning; A Bianchi; Kenneth F Bradstock
Functional and phenotypic upregulation of CD13/aminopeptidase-N on precursor-B acute lymphoblastic leukemia after in vitro stimulation.
Experimental hematology 1995;23(11):1173-9.
1995: Emmanuel Favaloro; DA Facey; L Grispo
Laboratory assessment of von Willebrand factor. Use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight VWF forms.
American journal of clinical pathology 1995;104(3):264-71.
1995: Emmanuel Favaloro; T Browning; H Nandurkar; M Sartor; Kenneth F Bradstock; Jerry Koutts
Aminopeptidase-N (CD13; gp 150): contrasting patterns of enzymatic activity in blood from patients with myeloid or lymphoid leukemia.
Leukemia research 1995;19(9):659-66.
1995: John Rasko; K N North; Emmanuel Favaloro; L Grispo; M C Berndt
Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1.
British journal of haematology 1995;89(3):582-8.
1994: PT van Hal; J P Hopstaken-Broos; A Prins; Emmanuel Favaloro; R J Huijbens; C Hilvering; Carl Figdor; Henk C Hoogsteden
Potential indirect anti-inflammatory effects of IL-4. Stimulation of human monocytes, macrophages, and endothelial cells by IL-4 increases aminopeptidase-N activity (CD13; EC 3.4.11.2).
Journal of immunology (Baltimore, Md. : 1950) 1994;153(6):2718-28.
1994: Emmanuel Favaloro; M Dean; L Grispo; T Exner; Jerry Koutts
von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.
American journal of hematology 1994;45(3):205-11.
1993: Emmanuel Favaloro
Differential expression of surface antigens on activated endothelium.
Immunology and cell biology 1993;71 ( Pt 6)():571-81.
1993: Emmanuel Favaloro; T Browning; DA Facey
CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated.
Experimental hematology 1993;21(13):1695-701.
1993: Emmanuel Favaloro; T Browning; H Nandurkar
The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150.
Clinica chimica acta; international journal of clinical chemistry 1993;220(1):81-90.
1993: Emmanuel Favaloro; L Grispo; A Dinale; M Berndt; Jerry Koutts
von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor.
Pathology 1993;25(2):152-8.
1993: A Srivastava; H Pearson; J Bryant; Emmanuel Favaloro; N Coulits; J Jindra; B Wylie
Acidified chloroquine treatment for the removal of class I HLA antigens.
Vox sanguinis 1993;65(2):146-50.
1992: Emmanuel Favaloro; E Bernal-Hoyos; T Exner; Jerry Koutts
Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis.
Pathology 1992;24(3):177-83.
1992: L C Dunlop; M P Skinner; Linda Bendall; Emmanuel Favaloro; P A Castaldi; Jeffrey J Gorman; Jennifer R Gamble; Mathew A Vadas; M C Berndt
Characterization of GMP-140 (P-selectin) as a circulating plasma protein.
The Journal of experimental medicine 1992;175(4):1147-50.
1991: Emmanuel Favaloro
CD-13 ('gp150'; aminopeptidase-N): co-expression on endothelial and haemopoietic cells with conservation of functional activity.
Immunology and cell biology 1991;69 ( Pt 4)():253-60.
1991: Emmanuel Favaloro; L Grispo; T Exner; Jerry Koutts
Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1991;2(2):285-91.
1990: Emmanuel Favaloro; N Moraitis; Kenneth F Bradstock; Jerry Koutts
Co-expression of haemopoietic antigens on vascular endothelial cells: a detailed phenotypic analysis.
British journal of haematology 1990;74(4):385-94.
1989: Emmanuel Favaloro; N Moraitis; Jerry Koutts; T Exner; K F Bradstock
Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens.
Thrombosis and haemostasis 1989;61(2):217-24.
1988: Emmanuel Favaloro; Kenneth F Bradstock; A Kabral; P Grimsley; H Zowtyj; H Zola
Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33.
British journal of haematology 1988;69(2):163-71.
1988: A Kabral; Kenneth F Bradstock; P Grimsley; Emmanuel Favaloro
Immunophenotype of clonogenic cells in myeloid leukaemia.
Leukemia research 1988;12(1):51-9.
1987: Emmanuel Favaloro; Kenneth F Bradstock; A Kabral; P Grimsley; M C Berndt
Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33).
Disease markers 1987;5(4):215-25.
1987: Emmanuel Favaloro; Kenneth F Bradstock; A Grimsley; A Henniker; S Kamath
Further studies on the heterogeneity of antigens recognised by CD-1 monoclonal antibodies: distribution of epitopes and analysis of serological binding patterns.
Immunology and cell biology 1987;65 ( Pt 6)():517-27.
1987: Kenneth F Bradstock; M Stevens; M Bergin; L Dalla-Pozza; P Duval; Emmanuel Favaloro; A Kabral; A Kerr; CA Juttner; Heddy Zola
Transplantation of monoclonal antibody-purged autologous bone marrow for treatment of poor risk common acute lymphoblastic leukemia.
Australian and New Zealand journal of medicine 1987;17(3):283-9.
1987: Heddy Zola; A Potter; SH Neoh; CA Juttner; David N Haylock; A M Rice; Emmanuel Favaloro; A Kabral; Kenneth F Bradstock
Evaluation of a monoclonal IgM antibody for purging of bone marrow for autologous transplantation.
Bone marrow transplantation 1987;1(3):297-301.
1986: Emmanuel Favaloro; Kenneth F Bradstock; S Kamath; G Dowden; D Gillis; V George
Characterization of a p43 human thymocyte antigen.
Disease markers 1986;4(4):261-70.
1986: Kenneth F Bradstock; A Kerr; A Kabral; Emmanuel Favaloro; J W Hewson
Coexpression of p165 myeloid surface antigen and terminal deoxynucleotidyl transferase: a comparison of acute myeloid leukaemia and normal bone marrow cells.
American journal of hematology 1986;23(1):43-50.
1986: Kenneth F Bradstock; Emmanuel Favaloro; A Kabral; A Kerr; M Prendergast; M C Berndt; W G Hughes; Heddy Zola; R Krishnan; David N Haylock
Standardization of monoclonal antibodies for use in autologous bone marrow transplantation for common acute lymphoblastic leukemia.
Pathology 1986;18(2):197-205.
1985: Kenneth F Bradstock; Emmanuel Favaloro; A Kabral; A Kerr; W G Hughes; E Musgrove
Myeloid progenitor surface antigen identified by monoclonal antibody.
British journal of haematology 1985;61(1):11-20.
1985: Kenneth F Bradstock; Emmanuel Favaloro; A Kabral; A Kerr; W G Hughes; M C Berndt; E Musgrove
Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells.
Pathology 1985;17(3):392-9.
1982: R M Case; A D Conigrave; Emmanuel Favaloro; I Novak; C H Thompson; J A Young
The role of buffer anions and protons in secretion by the rabbit mandibular salivary gland.
The Journal of physiology 1982;322():273-86.